Multibagger Pharma Stock Sets Record Date For Dividend, Prabhudas Lilladher Assigns Buy Call

Leading multibagger pharmaceuticals sector stock, Torrent Pharmaceuticals Ltd has fixed February 3, 2023 as record date for interim dividend, if declared. Prabhudas Lilladher in its October 25, 2022 brokerage report has assigned buy call to Torrent Pharmaceuticals with a target price of Rs 1850 apiece. If you buy the stock at current market price of Rs 1543 apiece, you will get 20% return. Check details below:

1. Torrent Pharmaceuticals Fixes Record Date For Dividend

The board of directors of the company said in the regulatory filing, "Pursuant to Regulation 42 of Listing Regulations, the Company has fixed Friday, 3rd February, 2023 as the Record Date for taking record of the Members of the Company for the purpose of payment of Interim Dividend, if declared by the Board at their meeting scheduled to be held on Wednesday, 25th January, 2023."

Meanwhile, the board of directors of the company will hold a meeting on January 25, 2023 to consider and approve Audited Financial Results on Standalone basis and Unaudited Financial Results (with limited review) on Consolidated basis of the Company for the quarter and nine months ended on 31-Dec-22. The Board would also consider payment of Interim Dividend for the year 2022-23.

2. Torrent Pharmaceuticals Stock Performance & Return

The last trading price of the stock is Rs 1543 with 52-week high at Rs 1722 apiece and 52-week low at Rs 1242 apiece, respectively, The company has a market capitalisation of Rs 52,229 crore. The stock has given 124% return in last 5-years and 62% in last 3-years. It has declined 2% in last 1-year.

3. Valuation

According to brokerage firm Prabhudas Lilladher, "In the near term, Curatio acquisition will increase TRP's net debt and we see this acquisition as EPS dilutive. Historically TRP have managed to integrate successfully Unichem and Elder acquisition which gives us comfort. We expect 18% EBITDA and 19% EPS CAGR over FY22-25E. We maintain our estimates and 'BUY' rating with TP of Rs 1,850/share, 17x EV/EBITDA to Sept 2024E."

4. About Torrent Pharmaceuticals

The company was a pioneer in initiating the concept of niche marketing in India and today is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC), according to its official website. The large cap stock was incorporated in 1972.

Disclaimer

The stock has been picked from the brokerage report of Prabhudas Lilladher. Greynium Information Technologies, the Author, and the respective Brokerage House are not liable for any losses caused as a result of decisions based on the article. Goodreturns.in advises users to check with certified experts before taking any investment decision.